Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | OGG1 | O15527 | 1/20 | 0.43 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL7633145 | 0.84 | CARM1 (0.43) | ALDH1A1HSD17B10PGRGAAPTGS1 | |
| SCHEMBL246709 | 0.83 | ALDH1A1 (0.57) | ALDH1A1HSD17B10PGRGAAPTGS1 | |
| SCHEMBL8458747 | 0.83 | ALDH1A1 (0.57) | ALDH1A1HSD17B10PGRGAAPTGS1 | |
| SCHEMBL4600933 | 0.83 | ALDH1A1 (0.57) | ALDH1A1HSD17B10PGRGAAPTGS1 | |
| SCHEMBL28372888 | 0.81 | MAPT (0.53) | ALDH1A1GAAMAPK1KMT2AL3MBTL1 | |
| SCHEMBL9323234 | 0.80 | PTGS1 (0.50) | ALDH1A1HSD17B10PGRGAAPTGS1 | |
| SCHEMBL10714230 | 0.80 | ALDH1A1 (0.60) | ALDH1A1HSD17B10PGRGAAPTGS1 | |
| SCHEMBL10713841 | 0.80 | ALDH1A1 (0.60) | ALDH1A1HSD17B10PGRGAAPTGS1 | |
| SCHEMBL27577951 | 0.79 | HTR1B (0.51) | ALDH1A1HSD17B10PGRGAAPTGS1 | |
| SCHEMBL12396105 | 0.79 | ANPEP (0.51) | ALDH1A1HSD17B10PGRGAAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128955-A1 | Method of isolating (R)-tofisopam | VELA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | US | disclosed |
| CN-1547567-A | Chiral resolution method for producing compounds useful in the synthesis of taxanes | ���ƹɷ�����˾ | 2004-11-17 | — | — | CN | disclosed |
| CN-1168701-C | Method for purifying branched chain amino acids | 味之素株式会社 | 2004-09-29 | — | — | CN | disclosed |
| US-6653501-B2 | Using chromatographic process for separating a target chiral compound from its enantiomer in a racemic mixtures; purification | NAPRO BIOTHERAPEUTICS, INC. | 2003-11-25 | — | — | US | disclosed |
| CN-1334727-A | Method and composition for treating and preventing tuberculosis | SARAWAK MEDICHEM PHARMACEUTICALS INC (US) | 2002-02-06 | — | — | CN | disclosed |
| US-6072083-A | Method for purifying branched chain amino acids | AJINOMOTO CO., INC. (JP) | 2000-06-06 | — | — | US | disclosed |
| EP-0861826-B1 | Method for purifying branched chain amino acids | AJINOMOTO KK (JP) | 2000-04-26 | — | — | EP | disclosed |
| CN-1197060-A | Method for purifying branched chain amino acids | AJINOMOTO KK (JP) | 1998-10-28 | — | — | CN | disclosed |
| EP-0861826-A1 | Method for purifying branched chain amino acids | Ajinomoto Co., Inc. (JP) | 1998-09-02 | — | — | EP | disclosed |
| US-5487831-A | FULLERENES IMMOBILIZED ON SUPPORT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1996-01-30 | — | — | US | disclosed |
| US-5338529-A | Chromatography detection, separation of fullerenes | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-08-16 | — | — | US | disclosed |
| WO-1993022272-A1 | RECOGNITION AND SEPARATION OF CARBON CLUSTERS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1993-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128955-A1 | Method of isolating (R)-tofisopam | NPEPPS, NPPA, THOP1 | ALDH1A1 3345/4885HSD17B10 2513/4885PGR 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.